Markwell Clarizio LLP

Menu
Contact Us

Author name: Dino Clarizio

Litigating Trademark Disputes in Canada – What IP Practitioners Should Know

Trademarks /

The process of litigating trademark disputes in Canada bears many similarities to other common law jurisdictions, in particular the United States. However, there are some unique aspects of Canadian procedure that IP practitioners in other jurisdictions should know. This short article provides a brief overview of how trademark disputes are litigated in Canada. 1.                  Trademark […]

Litigating Trademark Disputes in Canada – What IP Practitioners Should Know Read More »

Federal Court finds Jamp’s nintedanib capsules to infringe Boehringer’s use patent but not its formulation patent

IP Decisions /

On August 8, 2024, the Federal Court (per Furlanetto J.) held that a patent directed to nintedanib for use in the prevention or treatment of idiopathic pulmonary fibrosis (“IPF”) was valid and infringed, while a patent directed to formulations of nintedanib was not infringed.  Boehringer Ingelheim (Canada) Ltd. et al v. Jamp Pharma Corporation, 2024

Federal Court finds Jamp’s nintedanib capsules to infringe Boehringer’s use patent but not its formulation patent Read More »

Federal Court of Appeal Confirms That Cialis Patent is Invalid

IP Decisions /

The Federal Court of Appeal (per Locke JA.) affirmed a trial decision in which claims in Lilly’s patent covering physiologically acceptable salts of tadalafil were found to be invalid for overbreadth and insufficiency. The principal issue on appeal was the proper construction of the claim term “physiologically acceptable”, though the Court’s obiter statements regarding the

Federal Court of Appeal Confirms That Cialis Patent is Invalid Read More »

Claims to Dosing Regimens May Not Be Prohibited Methods of Medical Treatment: A Question of “Whether” and “How”

IP Decisions /

In Pharmascience v Janssen, the Federal Court of Appeal (Locke JA writing for the Court) held that the claims in Janssen’s patent to a dosing regimen are not prohibited as a method of medical treatment. Pharmascience v Janssen, 2024 FCA 23   The Prohibition Against Patenting Methods of Medical Treatment The patentability of methods of

Claims to Dosing Regimens May Not Be Prohibited Methods of Medical Treatment: A Question of “Whether” and “How” Read More »

Federal Court Finds Takeda’s Patent Not infringed and Invalid for Inutility and Insufficiency

IP Decisions /

The Federal Court (per Furlanetto J.) held that Takeda’s 916 Patent covering aspects of its DEXILANT® capsules is not infringed by Apotex’s proposed generic dexlansoprazole capsules and, in any event, is invalid for inutility (lack of sound prediction) and insufficiency. Takeda Canada Inc. v. Apotex Inc. – Federal Court (fct-cf.gc.ca) The Court’s infringement and validity

Federal Court Finds Takeda’s Patent Not infringed and Invalid for Inutility and Insufficiency Read More »

Samsung and Biogen Enjoined From Using BYOOVIZ Trademark for their Biosimilar in Canada

IP Decisions /

The Federal Court (per Pallotta J.) held that Biogen’s and Samsung’s use of the mark BYOOVIZ in association with an ophthalmologic drug infringes Novartis’s trademark registration for BEOVU, and granted a permanent injunction preventing further use of the mark. Novartis v Biogen 2024 FC 52 Novartis is the owner in Canada of a trademark registration

Samsung and Biogen Enjoined From Using BYOOVIZ Trademark for their Biosimilar in Canada Read More »

Litigating Patents in Canada Compared to the U.S.A.

Uncategorized /

Some commentators have said the Inter Partes Review process and various U.S. Supreme Court decisions have recently made enforcement of patent rights in the United States more challenging. As a result, some patentees have looked abroad to places like Europe (especially Germany) to enforce their patent rights. But what about Canada? Why should an American

Litigating Patents in Canada Compared to the U.S.A. Read More »

Sandoz v. Janssen 2023 FCA 221: Threshold for Sound Prediction

IP Decisions /

The Federal Court of Appeal (Locke JA writing for the Court) recently confirmed the threshold for establishing a sound prediction of utility. Sandoz v Janssen 2023 FCA 221 Canadian patent law requires that, to prevent the filing of patent applications based on speculation, utility must be either demonstrated or the requirements for a sound prediction

Sandoz v. Janssen 2023 FCA 221: Threshold for Sound Prediction Read More »

Inducing Infringement with a Skinny Label: FCA Weighs-In

IP Decisions /

The Federal Court of Appeal (Locke JA writing for the Court) held that Apotex will induce infringement of patent claims to a combination of two active ingredients to treat a condition even though Apotex is seeking approval to market only one of the active ingredients as a monotherapy for the same condition. https://lnkd.in/gkb9faVi Janssen is the

Inducing Infringement with a Skinny Label: FCA Weighs-In Read More »